1Hooker DJ,Tachedjian G,Solomon AE, et al. An in vivo mutation form leucine to tryptophan at position 210 in human immunodeficiency virus type 1 reverse transcriptase contributes to high-level resistance to 3'-azido-3'deoxythymidine[J]. J Virol, 1996, 70:1
2Larder BA,Bloor S,Kemp SD,et al. Afamily of insertion mutations between codons 67 and 70 of human immunodeficiency virus type 1 reverse transcriptase confer multinucleoside analog resistance[J]. Antimicrob Agents Chemotherap, 1999,43:1961-1971.
3Tisdale M,Alnadaf T,Cousens D. Combination of mutations in human immunodeficiency virus type 1 reverse transcriptase required for resistance to the carbocyclic nucleoside 1592U89[J]. Antimicrob Agents CJhemotherap, 1997, 41, 1094-1098.
4Miller V,Sturmer M,Staszewski S,et al. The M184V mutation in HIV-1 reverse transcriptase(RT)conferring lamivudine resistance does not result in broad cross-resistace to nucleoside analogue PT inhibibors[J]. AIDS, 1998, 12:705-712.
5Shafer RW,Winters MA,palmer S, et al. Multiple concurrent reverse transcriptase and protease mutation and multidrug resistance of HIV-1 isolates from heavily treated patients[J]. Ann Intern Med, 1998, 128:951-954.
6Ren,J. Structural mechanisms of drug resistance for mutations at codons 181 and 188 in HIV-1 reverse transcriptase and the improved resilience of second generation onncleoside inhibitors[J]. J Mol Biol, 2001, 312: 795-805.
7Deeks S,Parkin A,Petropoulos C,et al. Correlation of baseline phenotypic drug susceptibility with 16 week virologic response in a pilot combination therapy study in HIV-infected patients who failed indinavir therapy[J]. Antiviral Ther, 1998,3(Suppl. 1):36
8Zolopa A,Shafer R,Warford A, et al. Predictors of antiviral response to SQV/RTV in a clinical cohort who have failed prior PIs:a comparison of clinical characteristics,antiretroviral drug history and HIV genotype[J]. Antiviral Ther, 1998,3(Suppl. 1):37.
9De Gruttola V,Dix L,D'Aquila R,et al. The relation between baseline HIV drug resistance and response to antiretroviral therapy:reanalysis of retrospective and prospective studies using a standardized data analysis plan[J]. Antiviral Ther,2000,5:41-48.
10Palmer S,Shafer RW,Merigan TC. Highly drug-resistant HIV-1 clinical isolates are cross-resistant to many antiretroviral compounds in current clinical development[J]. AIDS, 1999, 13:661-667.
